[
    [
        {
            "time": "2019-01-01",
            "original_text": "The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Citigroup",
                    "Novo Nordisk",
                    "BP",
                    "salesforce.com",
                    "TC Energy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "finance",
                    "energy",
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-02",
            "original_text": "Novo Nordisk’s Shares Are Rising Because Newer Diabetes Drugs Are Selling Well",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Shares Rising",
                    "Diabetes Drugs",
                    "Selling Well"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk’s Shares Are Rising Because Newer Diabetes Drugs Are Selling Well",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-01-03",
            "original_text": "UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "2019 sales outlook",
                    "new drugs",
                    "excel"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-04",
            "original_text": "Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "2019 sales outlook",
                    "new drugs",
                    "excel"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]